Cite

    Yoshinari Takaoka et al.. “Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.” Hepatology research, vol. 51, no. 1, 2021, pp. 51–61. http://access.bl.uk/ark:/81055/vdc_100119973876.0x00002c